Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourDescending Triangle
15 minBullish
5 minBearish
Daily trend turns up above $10.79
Key levels
Resistance$9.79
Resistance$9.13
Support$8.61
Support$6.68
Latest news & SEC filings
EarningsCore Laboratories Posts Q3 2026 Results
GuidanceCore Laboratories guides Q4 GAAP EPS to $0.12-$0.20, sales to $128.5M-$134.5M
EarningsCore Laboratories Posts $0.16 Adjusted Per-Share Profit, Revenue Slightly Under Target
All CLB news →Core Laboratories supplies reservoir description and production enhancement services and products to companies in the petroleum sector, including large international, state-owned, and smaller independent operators. Its Reservoir Description segment analyzes rock and fluid samples, while its Production Enhancement segment provides well completion, perforation, and stimulation technologies. The company runs laboratories and offices across many countries worldwide.
Based on the company's 10-K filed Mar 23, 2026.
· Energy
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CLB.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/E Forward
Fair Value
$7.46
30
Moat Score
NONE
7/9
Piotroski Score
2.3
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tattoli Mark Damian | officer | Sale | 276 | $3K | Oct 1, 2026 |
| Tattoli Mark Damian | officer | Buy | 700 | - | Oct 1, 2026 |
| Teo Sow Hang | officer | Sale | 99 | $966.24 | Oct 1, 2026 |
| Teo Sow Hang | officer | Buy | 250 | - | Oct 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
0.5%
3yr Revenue CAGR
2.4%
EPS Growth YoY
1.52%
FCF Growth YoY
-47.9%
Revenue Trend
SLOWING
SEPT Investing tracks real-time dark pool institutional trades for CLB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:17 | $9.04 | 4,033 | $$36K | SELL |
| 21:00:31 | $9.04 | 2,080 | $$19K | SELL |
| 21:00:30 | $9.04 | 3,094 | $$28K | SELL |
| 21:00:03 | $9.04 | 1,364 | $$12K | SELL |
| 20:56:23 | $9.05 | 1,300 | $$12K | SELL |
5 dark pool trades shown · $$107K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for CORE LABORATORIES N V (CLB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CORE LABORATORIES N V (CLB) is at $9.04, up 1.01% (+$0.09) at the Nov 11, 2026 close.
Latest CLB news — Oct 29, 2026: Core Laboratories Posts Q3 2026 Results · Oct 28, 2026: Core Laboratories guides Q4 GAAP EPS to $0.12-$0.20, sales to $128.5M-$134.5M
Analyst ratings for CLB: 2 Buy, 0 Hold, 1 Sell — consensus Buy.
CLB last reported on Jul 29, 2026: EPS $0.11 vs $0.09 expected — a beat of 26.6%.
Yes. CLB's dividend yield is 0.25%.
CORE LABORATORIES N V reported $206M of debt and $23M of cash (Dec 31, 2025).
Support: $8.61, $6.68. Resistance: $9.13, $9.79, $10.29.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Oct 29, 2026: Core Laboratories Posts Q3 2026 Results · Oct 28, 2026: Core Laboratories guides Q4 GAAP EPS to $0.12-$0.20, sales to $128.5M-$134.5M · Oct 28, 2026: Core Laboratories Posts $0.16 Adjusted Per-Share Profit, Revenue Slightly Under Target